

## Full-length article

**Ouabain induces cardiac remodeling in rats independent of blood pressure<sup>1</sup>**Xing JIANG<sup>2,4</sup>, Yan-ping REN<sup>3</sup>, Zhuo-ren LÜ<sup>3</sup><sup>2</sup>Geriatric-Cardiovascular Department, the People Hospital of Shaanxi Province and the Third Hospital of Xi'an Jiaotong University, Xi'an 710068, China; <sup>3</sup>Geriatric-Cardiovascular Department, First Hospital of Xi'an Jiaotong University, Xi'an 710061, China**Key words**

ouabain; cardiac remodeling; hypertension

<sup>1</sup> Project supported by the Natural Science Basic Research Plan in Shaanxi Province of China (Program No 2005C242)<sup>4</sup> Correspondence to Dr Xing JIANG.

Phn 86-29-8532-4042.

Fax 86-29-8265-5046.

E-mail jiangxinwind@126.com

Received 2006-07-16

Accepted 2006-09-21

doi: 10.1111/j.1745-7254.2007.00496.x

**Abstract**

**Aim:** To investigate the ouabain's effects on cardiac remodeling in rats. **Methods:** Male Sprague-Dawley rats were treated with ouabain. Systolic blood pressure (SBP) was recorded weekly. After 4 and 6 weeks, echocardiography were performed, hemodynamic parameters were measured by invasive cardiac catheterization, changes in cardiac ultrastructure were analyzed using transmission electron microscopy, the collagen fraction of the left ventricle was assessed with Picrosirius red stain, and RT-PCR was applied to evaluate the mRNA level of myosin heavy chain- $\alpha$  and - $\beta$  in the left ventricle. **Results:** Having been treated with ouabain for 4 weeks, there was no significant difference in the mean SBP of the two groups. However, left ventricular hypertrophy, myocardial ultrastructure deterioration, and extracellular matrix remodeling were induced by ouabain treatment; meanwhile, cardiac systolic and diastolic performance were both worsened. Moreover, the cardiac MHC- $\beta$  mRNA was upregulated by ouabain treatment, whereas MHC- $\alpha$  mRNA was downregulated. After 4 weeks, the mean SBP in the ouabain group began to increase and was significantly higher than that in control group after 6 weeks ( $P < 0.01$ ); the rats' cardiac structure and function were worsened. **Conclusion:** These results suggested that ouabain induces alterations in cardiac structure and function, and the effects happened before the increase of blood pressure. The results indicated that ouabain induced cardiac remodeling in rats independent of blood pressure.

**Introduction**

Ouabain is a steroid hormone which is released from the hypothalamus and the adrenal gland. Ouabain and other cardiac glycosides are known as specific inhibitors of sodium pumps ever since the very first observations of the inhibition of sodium pumps of red blood cells. As a sodium pump is an intrinsic plasma membrane enzyme that hydrolyses ATP to maintain the transmembrane gradients of  $\text{Na}^+$  and  $\text{K}^+$  found in most mammalian cells, as an inhibitor of sodium pumps, ouabain is implicated in sodium homeostasis and exerts direct actions on the vasculature, the heart<sup>[1]</sup>, and tubular sodium reabsorption<sup>[2]</sup>, thus playing an important role in the pathogenesis of hypertension and some other cardiovascular disorders.

There are many data suggesting that ouabain is associated with both high blood pressure and altered cardiac morphology in hypertensive patients<sup>[3,4]</sup>. For patients with more advanced hypertension, circulating levels of ouabain were directly related to both blood pressure and total peripheral resistance, and inversely related to cardiac index<sup>[4]</sup>. The presence of left ventricular hypertrophy with high plasma ouabain levels has been found to be associated with alterations in cardiac function<sup>[5]</sup>. The young offspring of hypertensive patients had higher plasma levels of ouabain than the offspring of normotensive parents, which were correlated with diastolic dysfunction<sup>[6]</sup>. Moreover, circulating ouabain is a novel, independent, and incremental marker that predicts the progression of heart failure according to Pitzalis's report<sup>[7]</sup>.

Although ouabain might have a primary role in causing cardiac dysfunction and failure, its precise role and mechanism remains unclear. Our research group proposed that ouabain at pathological concentrations might affect the structure and function of the vascular endothelium and trigger vascular remodeling in hypertension<sup>[8]</sup>. Due to the demonstrated effects of ouabain on vascular areas, an effect of ouabain on cardiac remodeling and function could be predicted, so it prompted us to investigate ouabain's contributions to the heart, on the assumption that ouabain might have a primary role in the progression of both vascular remodeling and cardiac remodeling in hypertension. This study investigated ouabain's effects on the rat heart in order to assess whether the steroid hormone affects the structure and function of the heart and if it is involved in cardiac remodeling.

## Materials and methods

**Reagents and drugs** Ouabain was purchased from Sigma (St Louis, MO, USA). Kits for RNA extraction and reverse transcription were purchased from Invitrogen (San Diego, CA, USA). The primers and probes were synthesized by Sangon Biological Engineering Technology and Service Co (Shanghai, China). All other reagents were of analytical grade.

**Established animal model** The rats used to establish the animal model were Grade II (Certificate No 08-005). The project was approved by the Animal Experimentation Ethics Committee of Xi'an Jiaotong University (Xi'an, China). For the experiments, 6–10-week-old male Sprague-Dawley rats (150–200 g) were used after being kept in a temperature-controlled room for a week. The rats were randomly assigned to the experimental and control groups. The rats in the former group ( $n=48$ ) received a maintenance dose of ouabain intra-peritoneally. On d 1, a loading dose of 34 mg/kg ip was administered, followed by a dose of 27.8 mg·kg<sup>-1</sup>·d<sup>-1</sup> ip for an additional 6 weeks every day. The control group ( $n=40$ ) received vehicle (0.9% saline) only. Ouabain was dissolved in sterile saline at a concentration of 20 mg/mL and stored for up to 1 week at 4 °C in the dark. Systolic blood pressure (SBP) was recorded with a tail cuff once a week using a heart rate and blood pressure recorder for rats (RBP-1B; China-Japan Clinical Medicine Institute, Beijing, China). The average of 3 recordings was taken as the individual SBP. Measurements obtained using this method correlated well with those obtained using the direct cannulation method<sup>[9]</sup>. The 8 rats whose blood pressure was unchanged by ouabain treatment (“ouabain-resistant” rats<sup>[8]</sup>) were excluded. The 2 groups of animals were kept in the same conditions

during the experiment. At the end of 4 and 6 weeks, echocardiography was performed, hemodynamic parameters were measured by invasive cardiac catheterization, and then the animals were sacrificed and the apical half of the ventricular tissues was collected for the experiments.

**Echocardiographic examination** Transthoracic echocardiography was performed on the anaesthetized rats using a Sonos 5500 echocardiographic system (Philips Medical Systems, Andover, MA, USA). The system was equipped with a 7–12 MHz transducer that was placed on the shaved left hemithorax. The parasternal long-axis views of the left ventricle at or just below the tip of the mitral valve leaflets were used to obtain targeted M-mode recordings. The left ventricular end-diastolic diameter (LVEDd) and end-systolic diameter (LVEDs), septal thickness (IVST) and posterior wall thickness (PWT) were measured. The pulsed Doppler recordings were made from the standard apical 4 chamber view. Some indexes of left ventricular filling by Doppler flow velocity were measured: the isovolumic relaxation time (IVRT), the peak velocity of early left ventricular filling (E), the peak velocity of late ventricular filling (A), and the ratio between the early and late peak flow velocity (E/A). All data given are the means for 5 consecutive cardiac cycles and all measurements were manually obtained by the same observer. Midwall fractional shortening (FS) was calculated as described by Shimizu *et al*<sup>[10]</sup>. The ejection fraction (EF) was measured using a modified version of Simpson's monoplane analysis<sup>[11]</sup>.

**Hemodynamic measurements** Hemodynamics data were obtained by catheterization of the right common carotid artery as described previously<sup>[12]</sup>. The carotid artery was isolated and cannulated with a 3-F high-fidelity microtip catheter connected through a data acquisition unit (PowerLab 4.12, AD Instruments Inc, Castle Hill, NSW, Australia) to a computer running MacLab software (AD Instruments Inc, Australia). The catheter was advanced into the left ventricle. After an equilibration period of 20 min, the left ventricular systolic pressures (LVSP) and end-diastolic pressures (LVEDP), and the left ventricular  $dp/dt_{max}$  were monitored. All hemodynamic parameters were recorded continuously for 15 min. Then the rats were sacrificed and the hearts were isolated rapidly. The left ventricles were cut into 2 pieces; one piece was fixed with 4% paraformaldehyde for histochemistry, and the other was stored in liquid nitrogen for real-time quantitative RT-PCR.

**Myocardial ultrastructure examination** The animals were anesthetized with 20% urethane ip, and the apical part of the ventricle was removed. The samples were chipped into tissue blocks of 1 mm<sup>3</sup> on ice and immediately put into a 2.5% glutaraldehyde fixation solution at 4 °C for 2 h. Electron

microscope slices were produced according to routine methods for the preparation of transmission electron microscope specimens. Ultrathin sections were stained with uranyl acetate and lead citrate for examination on a transmission electron microscope (Hitachi H600, Tokyo, Japan).

**Morphological examination** The samples of the left ventricle were fixed in 4% paraformaldehyde for 24 h, dehydrated in ethanol, cleared in dimethylbenzene, and embedded in paraffin. The sections were prepared and stained with Picrosirius red<sup>[13]</sup>. The slides were observed with a Nikon Microphot FXA light microscope (Tokyo, Japan) equipped with a polarized set. The collagen fraction of the left ventricle (CFLV) was assessed using Picrosirius red stain and calculated as described previously<sup>[14]</sup>. The CFLV was expressed as the mean percentage of connective tissue areas divided by the total tissue area in the same field. The operator was blinded to the experimental group during the analysis.

**RT-PCR primers and probes design** Primers and probes for quantitative RT-PCR were designed and synthesized by Sangon Biological Engineering Technology and Service Co (Shanghai, China). The melting temperature for the primers was set at 50–60 °C, but the probe's melting temperature was at least 10 °C higher. The minimum GC content for the primers and probes was 20%–80%, and runs of identical nucleotides were avoided. All the probes were labeled at the 5' end with the reporter dye molecule, FAM (6-carboxy-fluorescein), and at the 3' end with the quencher dye, TAMRA (6-carboxytetramethylrodamine; Table 1).

**Quantitative RT-PCR** The total RNA in the left ventricles was extracted using the Trizol Max kit (Invitrogen, USA). The expression of MHC- $\alpha$  and MHC- $\beta$  was examined by fluorescent real-time quantitative RT-PCR. The quantitative RT-PCR was performed using SuperScript one-step RT-PCR kit with the Platinum *Taq* system (Invitrogen, USA), following the manufacturer's instructions (with modifica-

tions). The cDNA amplification product was predicted to be a 164 bp fragment for MHC- $\alpha$ , and a 148 bp fragment for MHC- $\beta$ . A total reaction volume consisting of 1  $\mu$ L forward primer, 1  $\mu$ L reverse primer, 1  $\mu$ L fluorescent probe, and 1  $\mu$ L RT/Platinum *Taq* Mix, and 4  $\mu$ L total RNA was made up to 50  $\mu$ L with RNase-free water. One-step RT-PCR amplification was performed in the ABI Prism 7700 Sequence Detection System (Perkin-Elmer, Foster City, CA, USA). Thermal cycling conditions were as follows: 94 °C for 5 min, followed by 50 cycles of 94 °C for 30 s, 56 °C for 30 s, and 72 °C for 30 s, then 72 °C for 5 min, and finally the reaction was held at 4 °C. The housekeeping gene GAPDH was used to normalize samples to remove the impact of any variations in RNA loading. The  $2^{-\Delta\Delta CT}$  method was used to calculate relative changes in gene expression determined from the real-time quantitative RT-PCR experiment<sup>[15]</sup>.

**Statistical analysis** Data are expressed as mean $\pm$ SD. Statistical differences were determined by ANOVA with the SPSS software package (version 10.0). Student's *t*-test was employed to compare the data between the 2 groups. A probability value of  $P < 0.05$  was considered statistically significant.


## Results

**Effects of ouabain on SBP** In the 4 weeks, there was no significant difference in the mean SBP between the ouabain group and the control group ( $P > 0.05$ ). After 4 weeks, the mean SBP in the ouabain group began to increase and was significantly higher than that in control group after 6 weeks ( $P < 0.01$ ; Figure 1).

**Echocardiographic findings** Four weeks after treatment with ouabain, the rats in the ouabain group showed clear signs of left ventricle dysfunction, whereas the rats in the control group displayed normal echocardiographic

**Table 1.** Primers and probes for quantitative RT-PCR.

Gene name	Primer and probe
Myosin heavy chain- $\alpha$ (MHC- $\alpha$ )	Forward primer: 5'-CTG CTC TCC ACC GGG AAA AT-3' Reverse primer: 5'-GAT ACC CTC CAG CAC TCC GTT-3' Probe: 5'-FAM-CCTGGTCATGCACCAGCTGC-TAMRA-3'
Myosin heavy chain- $\beta$ (MHC- $\beta$ )	Forward primer: 5'-GAC GAA GTC TCC AGG GGT GAT-3' Reverse primer: 5'-GTT CAG GAT TCG ATA CCT CT-3' Probe: 5'-FAM-CAACGGAGTGCTGGAGGGTAT-TAMRA-3'
Housekeeping gene (GAPDH)	Forward primer: 5'-CCT CAA GAT TGT CAG CAA T-3' Reverse primer: 5'-CCA TCC ACA GTC TTC TGA GT-3' Probe: 5'-FAM-ACCACAGTCCATGCCATCAC-TAMRA-3'



**Figure 1.** Ouabain’s effects on systolic blood pressure (SBP). *n*=40. Mean±SD. <sup>c</sup>*P*<0.05 vs control.

parameters. Systolic performance worsened in the ouabain group, which is indicated by the reduced EF and FS. Diastolic performance was affected also, as shown by the decreased E/A and increased IVRT. LVEDs, LVEDd, PWT and IVST were significantly greater in the rats of the ouabain group, indicating that left ventricle enlargement and left ventricle wall thickening were induced by ouabain treatment (Table 2; Figure 2). Six weeks after treatment with ouabain,


echocardiographic parameters of the rats were more severe than that of the rats treated by ouabain for 4 weeks.

**Hemodynamic data** After treatment with ouabain for 4 weeks, there were no significant differences in the carotid blood pressure (CBP) of the 2 groups. However, compared with the normal control animals, LVSP and  $\pm dp/dt$  significantly decreased and LVEDP increased in the rats of the ouabain group. After treatment with ouabain for 6 weeks, the CBP in the ouabain group was significantly higher than that in the control group, and all hemodynamic results further deteriorated (Table 3).

**Changes in myocardial ultrastructure** Cardiac muscle fibers in the control group were abundant, with regular arrays of myofibrils closely arranged within the sarcomere. The mitochondria were intact and had no swelling or disruption. There were little collagen fibers between the myocardial cells in the control group. Cardiac muscle fibers, mitochondria, and collagen fibers in the ouabain group were significantly different from those in the control group. The differences included reduction of the sarcoplasm content, disorganization of myofilaments and Z line, mitochondrial swelling, disruption and vacuolation, and hyperplastic col-

**Table 2.** Echocardiographic findings of the 2 groups. *n*=10. Mean±SD. <sup>b</sup>*P*<0.05 vs control. <sup>c</sup>*P*<0.05 vs ouabain group in the fourth week.

	Four weeks		Six weeks	
	Ouabain group	Control group	Ouabain group	Control group
LVEDs (mm)	4.42±0.48 <sup>b</sup>	3.64±0.30	5.01±0.44 <sup>bc</sup>	3.63±0.37
LVEDd (mm)	7.29±0.45 <sup>b</sup>	6.52±0.23	7.43±0.41 <sup>b</sup>	6.42±0.16
PWT (mm)	1.73±0.09 <sup>b</sup>	1.58±0.10	1.86±0.09 <sup>bc</sup>	1.57±0.10
IVST (mm)	1.28±0.09 <sup>b</sup>	1.16±0.06	1.38±0.08 <sup>bc</sup>	1.17±0.03
IVRT (ms)	28.50±4.93 <sup>b</sup>	21.33±3.83	32.17±4.31 <sup>b</sup>	21.29±3.82
E/A	1.28±0.08 <sup>b</sup>	1.78±0.14	1.08±0.10 <sup>bc</sup>	1.81±0.11
EF (%)	73.84±3.65 <sup>b</sup>	81.03±3.94	69.47±2.66 <sup>bc</sup>	80.86±4.07
FS (%)	39.54±3.11 <sup>b</sup>	44.81±4.54	37.30±3.15 <sup>b</sup>	45.17±4.60



**Figure 2.** Echocardiographic pictures of the 2 groups. (A) 2-D echocardiography showed that the left ventricle was greater in the rat treated by ouabain for 4 weeks. (B) M-mode echocardiography indicated that the septum was thicker in the rat treated by ouabain for 4 weeks. (C) Normal septum in the rat of control group shown by M-mode echocardiography.


**Table 3.** Hemodynamic parameters of the 2 groups. *n*=10. Mean±SD. <sup>a</sup>*P*>0.05, <sup>b</sup>*P*<0.05 vs control. <sup>c</sup>*P*<0.05 vs ouabain group in the fourth week.

	Four weeks		Six weeks	
	Ouabain group	Control group	Ouabain group	Control group
CBP (mmHg)	124.17±4.26 <sup>a</sup>	122.83±6.34	133.33±5.72 <sup>bc</sup>	123.17±5.91
LVSP (mmHg)	114.33±6.98 <sup>b</sup>	126.67±5.82	103.50±8.19 <sup>bc</sup>	126.66±6.71
LVEDP (mmHg)	1.35±0.11 <sup>b</sup>	-1.11±0.09	1.47±0.11 <sup>b</sup>	-1.10±0.06
+dp/dt (mmHg/s)	5045.67±327.08 <sup>b</sup>	5587.50±365.10	4502.17±365.68 <sup>bc</sup>	5659.33±358.58
-dp/dt (mmHg/s)	-3829.67±280.16 <sup>b</sup>	-4491.35±334.88	-3335.86±275.09 <sup>bc</sup>	-4481.00±251.40


lagen fibers. The differences were obvious in the rats treated with ouabain for 4 weeks (Figure 3).

**Morphometric histology** After treatment with ouabain

for 4 weeks, Picosirius red observation under polarized light showed that CFLV significantly increased in the rats of the ouabain group, which indicated that the collagen metabo-




**Figure 3.** Effects of ouabain on myocardial ultrastructure. (A) Cardiac muscle fibers and mitochondria in control group. (B) Hyperplasty, swelling, vacuolization of mitochondria and myofibrillar derangement in the rat treated by ouabain for 4 weeks. (C) Collagen fibers between myocardial cells in control group. (D) Hyperplastic collagen fibers in the rat treated by ouabain for 4 weeks. ×10000



**Figure 4.** Effects of ouabain on left ventricular collagen, stained with Picosirius red and observed under polarized light. (A) ouabain group in the fourth week. (B) control group.  $\times 100$ .

lism in left ventricle was affected by ouabain treatment [at 4 weeks  $5.97 \pm 0.39$  (ouabain group) vs  $4.92 \pm 0.50$  (control group); at 6 weeks  $6.38 \pm 0.53$  vs  $5.05 \pm 0.62$ ,  $P < 0.05$ ].

**Expression of MHC- $\alpha$  and MHC- $\beta$  mRNA in the left ventricles** After treatment with ouabain for 4 weeks, real-time quantitative RT-PCR showed a  $0.74 \times$  fold decrease ( $0.65-0.83$ , CV 10.81%) of MHC- $\alpha$  mRNA expression in the ouabain-treated rats compared with the vehicle rats. In contrast, MHC- $\beta$  mRNA expression increased  $2.26 \times$  fold ( $1.93-2.58$ , CV 14.60%). Six weeks after treatment with ouabain, MHC- $\alpha$  mRNA expression decreased  $0.55 \times$  fold ( $0.43-0.67$ , CV 21.82%), and MHC- $\beta$  mRNA increased  $3.28 \times$  fold ( $2.83-3.73$ , CV 13.41%) compared with the control group (Figure 5).



**Figure 5.** Effects of ouabain on MHC- $\alpha$  and MHC- $\beta$  mRNA expression in the left ventricles.  $n=7$ . Mean $\pm$ SD. <sup>b</sup> $P < 0.05$  vs control. <sup>e</sup> $P < 0.05$  vs ouabain group in the fourth week.

### Discussion

It has been demonstrated that ouabain administered ip is readily absorbed, and that plasma ouabain levels are not significantly different between intraperitoneal and intravenous groups at 10 min after administration<sup>[16]</sup>. The doses of ouabain infused in our study were determined based on previously published pharmacokinetic data for ouabain in rats. The doses administered were estimated to increase average plasma levels 0.5–1.0 nmol/L above the physical level<sup>[17]</sup> (the physical concentration of plasma ouabain is approximately 0.3–0.9 nmol/L<sup>[18]</sup>), so the plasma ouabain concentration in the animals is similar to the levels present in many pathological states such as hypertension and congestive heart failure (the pathological concentration of plasma ouabain is approximately 0.9–1.8 nmol/L<sup>[18]</sup>). Moreover, based on the animals' weight gain, behavioral changes, and cardiac rhythms, the effects of ouabain did not appear to be associated with substantial toxicity.

In this study, we investigated ouabain's effects on cardiac remodeling in rats. The primary findings are as follows: left ventricular hypertrophy, myocardial ultrastructure deterioration, and extracellular matrix remodeling were induced by ouabain treatment; meanwhile, cardiac systolic and diastolic performance both worsened. Moreover, the cardiac MHC- $\beta$  mRNA, a marker of hypertrophy or failure, was upregulated by ouabain treatment, whereas MHC- $\alpha$  mRNA was downregulated. The effects of ouabain were found before the increase of blood pressure, indicating that ouabain might damage the structure and function of the rat heart and be involved in cardiac remodeling independent of blood pressure.

There are other studies providing evidence that ouabain may cause pathological cardiac hypertrophy independent of blood pressure. In a study in rats, a chronic infusion of

very low doses of ouabain to double the plasma concentration of ouabain triggered a signal transduction pathway that produced cardiac hypertrophy<sup>[5]</sup>. Another study showed that partial inhibition of Na<sup>+</sup>/K<sup>+</sup> ATPase by ouabain causes hypertrophic growth and transcriptional regulation of several growth-related marker genes in cultured neonatal rat cardiac myocytes<sup>[19]</sup>.

However, how does ouabain exert such effects without a change in blood pressure? Recent studies have provided novel insights into ouabain's role. When ouabain binds to Na<sup>+</sup>/K<sup>+</sup> ATPase, it converts the enzyme to a signal transducer and initiates multiple gene regulatory pathways<sup>[19]</sup>; the cellular effects of ouabain on the heart may include actions independent of Na<sup>+</sup>/K<sup>+</sup> ATPase inhibition<sup>[20]</sup>. We suppose that the mechanisms underlying these actions of ouabain are as follows: first, ouabain interaction with Na<sup>+</sup>/K<sup>+</sup> ATPase initiates multiple growth-related gene regulatory pathways, triggers growth and the proliferation of cardiac myocytes and fibroblasts. It is reported<sup>[19]</sup> that ouabain's effects includes the activation of the Src kinase and tyrosine phosphorylation of the epidermal growth factor receptors and other proteins, followed by the activation of Ras, the Ras/Raf/MEK//MAPK cascade, and increased production of reactive oxygen species. Thus, cardiac hypertrophy and extracellular matrix remodeling are induced by ouabain treatment. Second, ouabain is a steroid hormone in nature; it has a complicated interaction with other neurohormonal systems, such as the renin-angiotensin and the endothelin system<sup>[21]</sup>. Saunders and Scheiner-Bobis suggest that ouabain stimulates endothelin release and expression in human endothelial cells<sup>[22]</sup>. Our research group previously found that plasma angiotensin (Ang) II and endothelin were increased by ouabain treatment in rats<sup>[23,24]</sup>. It is well known that Ang II and endothelin have toxic effects on cardiac myocytes and play an important role in the development of pathological cardiac remodeling. Ouabain's effects on the renin-angiotensin and the endothelin system might be involved in the damage of cardiac structure and function.

Echocardiography is one of the most widely used, noninvasive techniques to provide quantitative measurements of ventricular structure and function in humans and experimental animals. In rats, the heart is generally 1 g in weight with a 2 mm left ventricle wall thickness and a rapid heart rate of 300–400 bpm. Conventional transthoracic echocardiography transducers often do not provide enough resolution. However, high-frequency transducers (7.5–15 MHz) are now available to monitor morphometric and func-

tional changes in small animals *in vivo*<sup>[25]</sup>. Hemodynamics monitoring is one of the reliable methods to evaluate left ventricle performance by invasive catheterization. We chose the 2 kinds of techniques to evaluate ouabain's effects on the function of the rat heart.

Our results suggested that systolic and diastolic performance both worsened with ouabain treatment. Hypertrophic left ventricle and hyperplastic collagen fibers might be the reasons of diastolic dysfunction. The reasons for systolic dysfunction are multiple. At first our study showed that the mitochondria were damaged by ouabain treatment, and deteriorated energy metabolism could be predicted. Ouabain might affect systolic performance through disturbing the energy metabolism of cardiac myocytes. Second, the hypertrophy-associated switch of adult and fetal isoforms of myosin heavy chain expression might contribute to the systolic dysfunction in the ouabain-treated rats. In normal young adult rats, 80%–90% of the myosin heavy chain expressed is the  $\alpha$  isoform<sup>[26]</sup>. The MHC- $\alpha$  is associated with higher ATPase activity, and so hearts rich in MHC- $\alpha$  have a high intrinsic contractility. In contrast, MHC- $\beta$  is associated with low ATPase activity and a low intrinsic contractility. As showed in this study, decreased MHC- $\alpha$  mRNA expression and increased MHC- $\beta$  mRNA expression were induced by ouabain treatment, so the animal's cardiac systolic performance was affected. Finally, as an inhibitor of Na<sup>+</sup>/K<sup>+</sup> ATPase, a short-term administration of ouabain can exert a positive inotropic effect on cardio-myocytes by inhibiting the plasma membrane Na<sup>+</sup>/K<sup>+</sup> ATPase, increasing the intracellular Ca-concentration and decreasing the Ca-extrusion by the sodium/calcium exchanger (NCX). However, there are data suggesting that long-term administration of ouabain has no effect on myocardial contractility in rats. According to Muller-Ehmsen *et al*<sup>[27]</sup>, chronic ouabain treatment increases the protein expression of the NCX, and the positive inotropic effect can no longer be observed after chronic treatment for 2 d. Further more, NCX overexpression impairs ouabain-dependent cell shortening in adult rat cardiomyocytes<sup>[28]</sup>. In this study, chronic ouabain treatment for 4 or 6 weeks might induce NCX overexpression, and myocardial contractility might be impaired subsequently; this may be one of the ways through which ouabain affects systolic performance.

In conclusion, our study provides evidence that ouabain might damage the structure and function of the rat heart independent of blood pressure. Ouabain does not only trigger mechanisms initiating primary hypertension, but also

plays an important role in the development of cardiac remodeling. Clinical research during the past several decades has shown the importance of cardiac remodeling as a basic mechanism in the progression of heart failure. In the future, these novel insights into the role of ouabain in cardiac remodeling might allow the development of novel therapeutic strategies to treat cardiac remodeling and failure.

### Acknowledgement

We would like to thank all the other members of our ouabain research group for their suggestions and technical assistance.

### References

- 1 Schoner W. Endogenous cardiac glycosides, a new class of steroid hormones. *Eur J Biochem* 2002; 269: 2440–8.
- 2 Manunta P, Messaggio E, Ballabeni C, Sciarrone MT, Lanzanic C, Ferrandi M, *et al*. Plasma ouabain-like factor during acute and chronic changes in sodium balance in essential hypertension. *Hypertension* 2001; 38: 198–203.
- 3 Manunta P, Stella P, Rivera R, Ciurlino D, Cusi D, Ferrandi M, *et al*. Left ventricular mass, stroke volume, and ouabain-like factor in essential hypertension. *Hypertension* 1999; 34: 450–6.
- 4 Pierdomenico SD, Bucci A, Manunta P, Rivera R, Ferrandi M, Hamlyn JM, *et al*. Endogenous ouabain and hemodynamic and left ventricular geometric patterns in essential hypertension. *Am J Hypertens* 2001; 14: 44–50.
- 5 Ferrandi M, Molinari I, Barassi P, Minotti E, Bianchi G, Ferrari P. Organ hypertrophic signaling within caveolae membrane subdomains triggered by ouabain and antagonized by PST 2238. *J Biol Chem* 2004; 279: 33 306–14.
- 6 Manunta P, Iacoviello M, Forleo C, Messaggio E, Hamlyn JM, Lucarelli K, *et al*. High circulating levels of endogenous ouabain in the offspring of hypertensive and normotensive individuals. *J Hypertens* 2005; 23: 1677–81.
- 7 Pitzalis MV, Hamlyn JM, Messaggio E, Iacoviello M, Forleo C, Romito R, *et al*. Independent and incremental prognostic value of endogenous ouabain in idiopathic dilated cardiomyopathy. *Eur J Heart Fail* 2006; 8: 179–86.
- 8 Ren YP, Huang RW, Lv ZR. Ouabain at pathological concentrations might induce damage in human vascular endothelial cells. *Acta Pharmacol Sin* 2006; 27: 165–72.
- 9 Tipton CM, Sebastian LA, Overton JM, Woodman CR, Williams SB. Chronic exercise and its hemodynamic influences on resting blood of hypertension rats. *J Appl Physiol* 1991; 71: 2206–11.
- 10 Shimizu G, Hirota Y, Kita Y, Kawamura K, Saito T, Gaasch WH. Left ventricular midwall mechanics in systemic arterial hypertension. Myocardial function is depressed in pressure-overload hypertrophy. *Circulation* 1991; 83: 1676–84.
- 11 Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, *et al*. Recommendations for quantification of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on quantification of two-dimensional echocardiograms. *J Am Soc Echocardiogr* 1989; 2: 358–67.
- 12 Hou XW, Son J, Wang Y, Ru YX, Lian Q, Majiti W, *et al*. Granulocyte Colony-Stimulating Factor Reduces Cardiomyocyte Apoptosis and Improves Cardiac Function in Adriamycin-Induced Cardiomyopathy in Rats. *Cardiovasc Drugs Ther* 2006; 20: 85–91.
- 13 Zhang H, Sun L, Wang W, Ma X. Quantitative analysis of fibrosis formation on the microcapsule surface with the use of picrorhizus red staining, polarized light microscopy, and digital image analysis. *J Biomed Mater Res A* 2006; 76: 120–5.
- 14 Tao X, Liu GL. Protection of organic trauma in sinoaortic-denervated rats treated with fosinopril. *Acta Pharm Sin* 2003; 38: 743–7.
- 15 Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the  $2^{-\Delta\Delta CT}$  method. *Methods* 2001; 25: 402–8.
- 16 Wang H, Yuan WQ, Lu ZR. Differential regulation of the sodium pump  $\alpha$ -subunit isoform gene by ouabain and digoxin in tissues of rats. *Hypertens Res* 2000; 23: S55–60.
- 17 Tian G, Dang CX, Lu ZR. The changes and significance of the  $Na^+$ ,  $K^+$ -ATPase  $\alpha$ -subunit in ouabain-hypertensive rats. *Hypertens Res* 2001; 24: 729–34
- 18 Hamlyn JM, Manunta P. Ouabain, digitalis-like factors and hypertension. *J Hypertens* 1992; 10: S99–111.
- 19 Kometiani P, Li J, Gnudi L, Kahn BB, Askari A, Xie ZJ. Multiple signal transduction pathways link  $Na^+/K^+$ -ATPase to growth-related genes in cardiac myocytes. The roles of Ras and mitogen-activated protein kinases. *J Biol Chem* 1998; 273: 15 249–56.
- 20 Nishio M, Rush SW, Wasserstrom JA. Positive inotropic effects of ouabain in isolated cat ventricular myocytes in sodium-free conditions. *Am J Physiol Heart Circ Physiol* 2002; 283: H2045–53.
- 21 Xavier FE, Yogi A, Callera GE, Tostes RC, Alvarez Y, Salaices M, *et al*. Contribution of the endothelin and renin-angiotensin systems to the vascular changes in rats chronically treated with ouabain. *Br J Pharmacol* 2004; 143: 794–802.
- 22 Saunders R, Scheiner-Bobis G. Ouabain stimulates endothelin release and expression in human endothelial cells without inhibiting the sodium pump. *Eur J Biochem* 2004; 271: 1054–62.
- 23 Guo N, Jiang X, Lv ZR, Ai WT. The expression of angiotensin II and its subtype 1 and 2 receptors in the myocardium of ouabain-induced hypertensive rats. *J Xi'an Jiaotong Univ (Med Sci)* 2005; 26: 526–9. Chinese.
- 24 Jiang X, Guo N, Lv ZR, Ai WT. Effects of ouabain on endothelin system in rat heart. *J Xi'an Jiaotong Univ (Med Sci)* 2005; 26: 519–22. Chinese.
- 25 Kokubo M, Uemura A, Matsubara T, Murohara T. Noninvasive evaluation of the time course of change in cardiac function in spontaneously hypertensive rats by echocardiography. *Hypertens Res* 2005; 28: 601–9.
- 26 Nakanishi K, Nakata Y, Kanazawa F, Imamura SI, Matsuoka R,



- Osada H, *et al*. Changes in myosin heavy chain and its localization in rat heart in association with hypobaric hypoxia-induced pulmonary hypertension. *J Pathol* 2002; 197: 380–7.
- 27 Muller-Ehmsen J, Nickel J, Zobel C, Hirsch I, Bolck B, Brixius K, *et al*. Longer term effects of ouabain on the contractility of rat isolated cardiomyocytes and on the expression of Ca and Na regulating proteins. *Basic Res Cardiol* 2003; 98: 90–6.
- 28 Bolck B, Munch G, Mackenstein P, Hellmich M, Hirsch I, Reuter H, *et al*. Na<sup>+</sup>/Ca<sup>2+</sup> exchanger overexpression impairs frequency- and ouabain-dependent cell shortening in adult rat cardiomyocytes. *Am J Physiol Heart Circ Physiol* 2004; 287: H1435–45.
- 

## The 8<sup>th</sup> International Congress on SLE

May 23–27, 2007

Shanghai, China

[Http://www.chinamed.com.cn/lupus2007/](http://www.chinamed.com.cn/lupus2007/)